Hear you - a Long memory some of us have for understandable reasons
Do think the baystreet article nicely captured OM mkt - excellent summary of lay-o-land (need, players) ... a concise read
“With no approved drugs, there is no leader, meaning there’s a blue-sky opportunity for drugs that make it to market.”
Also like how it drew attn to IPIX and Enzychem setting higher bar as to Efficacy — Primary as Incidence and not Duration, like most others... what I was harping on over the weekend when boo birds started booing (setting up strawmen re results)
Anyhow, topline results need not even be stellar, just solid, and good things should follow, especially if Secondary endpoints deliver as well... Long-awaited share price climb, partner, uplist, etc.... not to mention on the way hopefully to healthier patients and happier family members via P/B/K
“Companies like those above are pioneers using new approaches, in some cases completely new classes of drugs, to make substantial advancements to successfully navigate their treatments into mid- and late-stage trials. Fingers crossed, one day soon there will be a watershed moment in OM when one – or maybe in multiple – drugs are available, filling a big void in cancer care.”
News 
Market Data 
Discover 
